From Evidence to Insight: KEYNOTE-689 Trial and Editorial on Harnessing Immunotherapy in Head and Neck Cancer
The New England Journal of Medicine (NEJM) shared a post on X about 2 of their papers:
“Original Article: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer (KEYNOTE-689 phase 3 trial).
Editorial: Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer.”
Pramesh CS, Director of the Tata Memorial Hospital, shared this post, adding:
“Given the epidemiology characteristics of head and neck cancer (predominantly lower socioeconomic population in LMICs), this NEJM published ‘breakthrough’ will benefit less than 10% of patients who would have otherwise benefited from it. Cost matters. This is NOT global oncology.”
Title: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
Authors: Ravindra Uppaluri, Robert I. Haddad, Yungan Tao, Christophe Le Tourneau, Nancy Y. Lee, William Westra, Rebecca Chernock, Makoto Tahara, Kevin J. Harrington, Arkadiy L. Klochikhin, Irene Braña, Gustavo Vasconcelos Alves, Brett G. M. Hughes, Marc Oliva, Iane Pinto Figueiredo Lima, Tsutomu Ueda, Tomasz Rutkowski, Ursula Schroeder, Paul-Stefan Mauz, Thorsten Fuereder, Simon Laban, Nobuhiko Oridate, Aron Popovtzer, Nicolas Mach, Yevhen Korobko, Diogo Alpuim Costa, Anupama Hooda-Nehra, Cristina P. Rodriguez, R. Bryan Bell, Cole Manschot, Kimberly Benjamin, Burak Gumuscu, Douglas Adkins
You can read the Full Article in NEJM.
Title: Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer
Authors: Ari J. Rosenberg, Everett E. Vokes
You can read the Full Article in NEJM.
More posts featuring NEJM.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023